Diabetes medications and cancer: A way out of uncertainty

Diabetes Research and Clinical Practice

Volumn 97, Issue 2, 2012, Pages 175-177

  Gallo, Marco ^a   Esposito, Katherine ^b   Giugliano, Dario ^b  

^a MOLINETTE HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DAPAGLIFLOZIN; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; RECOMBINANT HUMAN INSULIN;

BLADDER CANCER; BLADDER TUMOR; BREAST TUMOR; CANCER GROWTH; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG INDUCED CANCER; DRUG SAFETY; DRUG USE; HUMAN; LUNG CANCER; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PATIENT SAFETY; RISK ASSESSMENT;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; NEOPLASMS; OBESITY; RISK FACTORS;

EID: 84865072055     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.04.007     Document Type: Note

References (31)

1. Renehan A., Smith U., Kirkman M.S. Linking diabetes and cancer: a consensus on complexity. Lancet 2010, 375:2201-2202.
2. Giugliano D, Chiodini P, Colao A, Lenzi A, Esposito K. Metabolic syndrome and risk of cancer: a meta-analysis Diabetes Care; in press.
3. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
4. Larsson S.C., Orsini N., Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:1679-1687.
5. Huxley R., Ansary-Moghaddam A., Berrington de González A., Barzi F., Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005, 92:2076-2083.
6. Hemkens L.G., Grouven U., Bender R., Günster C., Gutschmidt S., Selke G.W., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009, 52:1732-1744.
7. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
8. Colhoun H.M. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009, 52:1755-1765.
9. Jonasson J.M., Ljung R., Talbäck M., Haglund B., Gudbjörnsdòttir S., Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009, 52:1745-1754.
10. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., et al. Diabetes and cancer: a consensus report. Diabetes Care 2010, 33:1674-1685.
11. US Food and Drug Administration: FDA Drug Safety Communication: update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. Available from: [accessed 19.03.12]. http://www.fda.gov/Drugs/DrugSafety/ucm239376.htm.
12. Suissa S., Azoulay L., Dell'Aniello S., Evans M., Vora J., Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011, 54:2254-2262.
13. Ruiter R., Visser L.E., van Herk-Sukel M.P., Coebergh J.W., Haak H.R., Geelhoed-Duijvestijn P.H., et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012, 55:51-62.
14. Jorgensen L., Dideriksen L., Drejen K. Carcinogenic effect of human insulin and B10Asp in female rats. Diabetologia 1992, 35(Suppl. 1):A3.
15. Mathieu C., Gale E.A. Inhaled insulin: gone with the wind?. Diabetologia 2008, 51:1-5.
16. von Kriegstein E., von Kriegstein K. Inhaled insulin for diabetes mellitus. N Engl J Med 2007, 356:2106.
17. Bowker S.L., Yasui Y., Veugelers P., Johnson J.A. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 2010, 53:1631-1637.
18. Elashoff M., Matveyenko A.V., Gier B., Elashoff R., Butler P.C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011, 141:150-156.
19. EASD commentary on the publication by Elashoff et al., published online in Gastroenterology, February 2011: increased incidence of pancreatitis and cancer among patients given glucagon like peptide-1-based therapy. Available from: [accessed 19.03.12]. http://www.easd.org/easdwebfiles/statements/Elashoff_Commentary.pdf.
20. US Food and Drug Administration: FDA Drug Safety Communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. Available from: [accessed 19.03.12]. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm.
21. European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer. Available from: [accessed 19.03.12]. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109176.pdf.
22. Gerich J.E., Bastien A. Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol 2011, 4:669-683.
23. Handelsman Y., Jellinger P.S. Overcoming obstacles in risk factor management in type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2011, 13:613-620.
24. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
25. Fanning E.L., Weissman P.N., Menditto L.A. Clinical practice effect of rosiglitazone discontinuation on glycemic control. Endocr Pract 2009, 15:270-272.
26. Giugliano D., Esposito K. Clinical inertia as a clinical safeguard. JAMA 2011, 305:1591-1592.
27. Stumvoll M., Nawroth P.P. The insulin glargine dilemma: an opportunity for the diabetes community?. Diabetologia 2009, 52:1987-1989.
28. Ceriello A., Gallo M., Armentano V., Perriello G., Gentile S., De Micheli A. Personalizing treatment in type 2 diabetes: a SMBG inclusive innovative approach. Diabetes Technol Ther 2012, 14:373-378.
29. Psarakis H.M. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectrum 2006, 19:157-162.
30. Currie C.J., Poole C.D., Jenkins-Jones S., Gale E.A., Johnson J.A., Morgan C.L. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 2012, 35:299-304.
31. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.